用于治疗肢端肥大症的生长抑素激动剂。
Somatostatin agonists for treatment of acromegaly.
作者信息
Ben-Shlomo Anat, Melmed Shlomo
机构信息
Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
出版信息
Mol Cell Endocrinol. 2008 May 14;286(1-2):192-8. doi: 10.1016/j.mce.2007.11.024. Epub 2007 Nov 29.
Abstract
The discovery of somatotropin-release inhibitory factor (SRIF) in hypothalamic extract in 1970 led to the synthesis of the first somatostatin analog octreotide, discovery of five somatostatin receptor subtypes, and development of additional somatostatin receptor ligands (SRL) as pharmacotherapy for acromegaly and other neuroendocrine tumors. Long-acting formulations of SRL (octreotide LAR Depot, lanreotide SR and lanreotide autogel) assure improved patient compliance with weekly up to monthly injections, and are commonly used as primary or adjuvant treatment of acromegaly. We review SRL currently available, emphasizing long-acting compounds and their efficacy in controlling acromegaly. Disease control is evaluated by biochemical markers, tumor shrinkage, and disease-symptom improvement balanced against drug-related side effects.
摘要
1970年在下丘脑提取物中发现生长激素释放抑制因子（SRIF），促使首个生长抑素类似物奥曲肽的合成、五种生长抑素受体亚型的发现以及其他生长抑素受体配体（SRL）作为肢端肥大症和其他神经内分泌肿瘤药物治疗的开发。SRL的长效制剂（奥曲肽长效释放微球、兰瑞肽SR和兰瑞肽凝胶）确保患者更好地依从性，从每周注射一次到每月注射一次，常用于肢端肥大症的一线或辅助治疗。我们回顾了目前可用的SRL，重点介绍长效化合物及其在控制肢端肥大症方面的疗效。通过生化指标、肿瘤缩小以及疾病症状改善与药物相关副作用的平衡来评估疾病控制情况。
相似文献
1
Somatostatin agonists for treatment of acromegaly.
Mol Cell Endocrinol. 2008 May 14;286(1-2):192-8. doi: 10.1016/j.mce.2007.11.024. Epub 2007 Nov 29.
2
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71. doi: 10.1046/j.0300-0664.2001.01438.x.
3
Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Neuroendocrinology. 2006;83(3-4):249-57. doi: 10.1159/000095535. Epub 2006 Oct 13.
4
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Endocr Relat Cancer. 2016 Dec;23(12):R551-R566. doi: 10.1530/ERC-16-0151. Epub 2016 Oct 3.
5
The Future of Somatostatin Receptor Ligands in Acromegaly.
J Clin Endocrinol Metab. 2022 Jan 18;107(2):297-308. doi: 10.1210/clinem/dgab726.
6
Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.
Eur J Endocrinol. 2016 Mar;174(3):355-62. doi: 10.1530/EJE-15-1042. Epub 2015 Dec 18.
7
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Pituitary. 2016 Apr;19(2):210-21. doi: 10.1007/s11102-015-0677-y.
8
Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Drugs. 2009 Nov 12;69(16):2207-26. doi: 10.2165/11318510-000000000-00000.
9
Discontinuation of somatostatin analogs while acromegaly is in long-term remission.
Pituitary. 2015 Aug;18(4):554-60. doi: 10.1007/s11102-014-0608-3.
10
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
J Clin Endocrinol Metab. 2008 Aug;93(8):2957-68. doi: 10.1210/jc.2008-0027. Epub 2008 May 13.
引用本文的文献
1
Biliary Tract Disorders and Associated Acute Complications in Patients With Acromegaly: A Single-Center Study.
J Clin Med Res. 2024 Apr;16(4):155-163. doi: 10.14740/jocmr5140. Epub 2024 Apr 30.
2
Regulation of FGF2-induced proliferation by inhibitory GPCR in normal pituitary cells.
Front Endocrinol (Lausanne). 2023 Jul 27;14:1183151. doi: 10.3389/fendo.2023.1183151. eCollection 2023.
3
Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas.
Cancers (Basel). 2023 Jun 30;15(13):3453. doi: 10.3390/cancers15133453.
4
Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study.
Ann Transl Med. 2022 Jul;10(13):734. doi: 10.21037/atm-22-414.
5
Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues.
Cell Discov. 2022 May 20;8(1):47. doi: 10.1038/s41421-022-00405-2.
6
Circulating miR-29c-3p is downregulated in patients with acromegaly.
Turk J Med Sci. 2021 Aug 30;51(4):2081-2086. doi: 10.3906/sag-2010-245.
7
Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST in Mediating Ligand Effects.
Cancers (Basel). 2021 Apr 10;13(8):1816. doi: 10.3390/cancers13081816.
8
Comparative distribution of somatostatin and somatostatin receptors in PTU-induced hypothyroidism.
Endocrine. 2020 Oct;70(1):92-106. doi: 10.1007/s12020-020-02309-1. Epub 2020 Apr 25.
9
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.
Int J Mol Sci. 2019 Aug 13;20(16):3940. doi: 10.3390/ijms20163940.
10
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
Pituitary. 2019 Feb;22(1):89-99. doi: 10.1007/s11102-018-0926-y.
本文引用的文献
1
Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.
J Clin Endocrinol Metab. 2007 May;92(5):1743-7. doi: 10.1210/jc.2006-2547. Epub 2007 Feb 20.
2
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.
J Endocrinol Invest. 2006 Dec;29(11):1017-20. doi: 10.1007/BF03349217.
3
Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.
Clin Endocrinol (Oxf). 2006 Nov;65(5):626-30. doi: 10.1111/j.1365-2265.2006.02639.x.
4
Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Clin Endocrinol (Oxf). 2006 Sep;65(3):320-6. doi: 10.1111/j.1365-2265.2006.02595.x.
5
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
J Clin Endocrinol Metab. 2006 Jun;91(6):2112-8. doi: 10.1210/jc.2005-2110. Epub 2006 Mar 14.
6
First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Clin Endocrinol (Oxf). 2006 Mar;64(3):342-51. doi: 10.1111/j.1365-2265.2006.02467.x.
7
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403. doi: 10.1210/jc.2005-2347. Epub 2006 Jan 31.
8
Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
Clin Endocrinol (Oxf). 2006 Feb;64(2):209-14. doi: 10.1111/j.1365-2265.2006.02450.x.
9
Consensus statement: medical management of acromegaly.
Eur J Endocrinol. 2005 Dec;153(6):737-40. doi: 10.1530/eje.1.02036.
10
Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.
Clin Endocrinol (Oxf). 2005 Nov;63(5):514-9. doi: 10.1111/j.1365-2265.2005.02372.x.
Zotero 插件